{"id":76519,"date":"2026-09-15T17:56:49","date_gmt":"2026-09-15T15:56:49","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/09\/15\/scopolamine-ameliorates-psoriasis-by-blocking-m1-receptor-mediated-il-23-production-in-dendritic-cells\/"},"modified":"2026-09-15T17:56:49","modified_gmt":"2026-09-15T15:56:49","slug":"scopolamine-ameliorates-psoriasis-by-blocking-m1-receptor-mediated-il-23-production-in-dendritic-cells","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/09\/15\/scopolamine-ameliorates-psoriasis-by-blocking-m1-receptor-mediated-il-23-production-in-dendritic-cells\/","title":{"rendered":"Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Aug 29;215(9):vkag179. doi: 10.1093\/jimmun\/vkag179.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Psoriasis is a chronic inflammatory skin disease involving intricate neuroimmune crosstalk. However, the specific mechanisms and therapeutic targets remain elusive. In this study, a pilot clinical trial demonstrated that intravenous scopolamine, a muscarinic receptor antagonist, significantly ameliorated skin lesions in psoriasis patients. Consistently, scopolamine reduced inflammation in an imiquimod-induced mouse model. Metabolomic profiling identified acetylcholine (ACh) as a significantly upregulated neurotransmitter in psoriatic skin, and exogenous ACh exacerbated inflammatory phenotypes. To pinpoint the cellular target, single-cell RNA sequencing revealed that dendritic cells (DCs), unlike T cells or macrophages, uniquely coexpressed neurointeraction receptors and the pathogenic cytokine Il23a. Mechanistically, scopolamine competitively inhibited ACh binding to M1 muscarinic receptors (M1Rs) on DCs, suppressing interleukin (IL)-23 secretion. This therapeutic efficacy was recapitulated in mice with DC-specific M1R deletion. Crucially, the protective effect of M1R deficiency was abolished by recombinant IL-23 administration, whereas scopolamine failed to inhibit inflammation induced by direct IL-23 injection, confirming its action upstream of cytokine release. Collectively, our findings provide compelling evidence that scopolamine treats psoriasis by antagonizing elevated ACh and blocking M1 receptor-mediated IL-23 release in DCs.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42742566\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260915115649&amp;v=2.20.1\">42742566<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag179\">10.1093\/jimmun\/vkag179<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Aug 29;215(9):vkag179. doi: 10.1093\/jimmun\/vkag179. ABSTRACT Psoriasis is a chronic inflammatory skin disease involving intricate neuroimmune crosstalk. However, the specific mechanisms and therapeutic targets remain elusive. In this study, a pilot clinical trial demonstrated that intravenous scopolamine, a muscarinic receptor antagonist, significantly ameliorated skin lesions in psoriasis patients. Consistently, scopolamine reduced inflammation in &#8230; <a title=\"Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/15\/scopolamine-ameliorates-psoriasis-by-blocking-m1-receptor-mediated-il-23-production-in-dendritic-cells\/\" aria-label=\"Read more about Scopolamine ameliorates psoriasis by blocking M1 receptor-mediated IL-23 production in dendritic cells\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-76519","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=76519"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76519\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=76519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=76519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=76519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}